Altimmune nears a key MASH trial readout, with strong market potential and new liver and alcohol studies supporting growth.

Altimmune stock rose on Tuesday without news, possibly due to high short interest. Its new trial for Alcohol Use Disorder and ...

Altimmune Inc. (NASDAQ:ALT) is poised for a potential breakthrough in the treatment of metabolic-associated steatohepatitis (MASH) and obesity with its lead candidate pemvidutide. With a market ...

Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it has enrolled ...

Altimmune Inc. (NASDAQ:ALT) is poised for a potential breakthrough in the treatment of metabolic-associated steatohepatitis (MASH) and obesity with its lead candidate pemvidutide. With a market ...

Altimmune Inc. research and ratings by Barron's. View ALT revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.

We recently published an article titled 13 Best Multibagger Stocks to Invest in Now. Altimmune, Inc. (NASDAQ:ALT) was one of ...

Altimmune’s Chief Medical Officer, Dr. Scott Harris, noted the potential of GLP-1 agents like pemvidutide to reduce alcohol cravings, referencing preclinical studies showing significant ...